Human Recombinant p16-INK4a-TAT (from E. coli)

Supplier: Peprotech

110-02T-5UG 110-02T-25UG 110-02T-100UG 110-02T-250UG 110-02T-500UG 110-02T-1MG
10772-336EA 132.81 USD
10772-336 10772-338 10772-340 10772-342 10772-344 10772-346
Human Recombinant p16-INK4a-TAT (from E. coli)
Proteins and Peptides

p16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin-dependent kinase-4 (CDK4) and CDK6. p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D. This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells. The expression of p16-INK4a steadily increases with age, and tends to accumulate in stem cell compartments. The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas, as well as in certain other types of cancer. p16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary, as well as transformed, cells. Recombinant Human p16-INK4a-TAT expressed in


Información para pedidos: For research use only. Not for use in diagnostic or therapeutic procedures.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR